Comparison Chart Arcus Biosciences, Inc.

Stocks

RCUS

US03969F1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 20:16:24 21/08/2026 +04			5-day change	1st Jan Change
30.40 ^USD	+2.98%		+2.87%	+27.26%

08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	ARCUS BIOSCIENCES, INC.	Other Biotechnology & Medical Research	+2.85%	+2.87%	+27.26%	+189.36%	+3.32%	3.76B